Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2018 Congress
October 10, 2018ACN Newswire
TOKYO, Oct 10, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts highlighting updates regarding its in-house discovered Lenvima/Kisplyx (lenvatinib mesylate, "lenvatinib", selective inhibitor of receptor tyrosine kinases with a novel binding mode) and Halaven (eribulin mesylate, "eribulin", halichondrin class microtubule dynamics inhibitor) will be presented during the European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich, Germany, from October 19 to 23, 2018.
At the ESMO 2018 Congress, there will be an oral presentation on tumor growth rate prior to treatment administration and efficacy of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
A total of five poster presentations are scheduled to be given, consisting of two presentations for lenvatinib, including the results of correlative analyses of serum biomarkers and efficiency outcomes for lenvatinib, everolimus and the combination of these two agents in metastatic renal cell carcinoma, and three presentations for eribulin.
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
About LENVIMA/KISPLYX (lenvatinib mesylate)
Discovered and developed in-house by Eisai, LENVIMA is an orally administered kinase inhibitor with a novel binding mode that selectively inhibits the multi activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRalpha; KIT; and RET) involved in tumor angiogenesis, tumor progression and modification of tumor immunity.
Currently, Eisai has obtained approval for LENVIMA as a treatment for refractory thyroid cancer in over 50 countries, including the United States, Japan, in Europe. Additionally, Eisai has obtained approval for the agent in combination with everolimus as a second-line treatment for renal cell carcinoma in over 45 countries, including the United States and in Europe. In Europe, the agent was launched under the brand name KISPLYX for renal cell carcinoma.
In addition, LENVIMA has been approved as a treatment for hepatocellular carcinoma in Japan, the United States, Europe, China and other countries. Eisai has submitted applications for an indication covering hepatocellular carcinoma in Taiwan (December 2017), as well as in other countries.
About the Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Strategic Collaboration
In March 2018, Eisai and Merck & Co., Inc. Kenilworth N.J., U.S.A., known as MSD outside of the U.S. and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc. Kenilworth N.J., U.S.A.'s anti-PD-1 therapy KEYTRUDA (pembrolizumab). In addition to ongoing clinical studies of the combination, the companies will jointly initiate new clinical studies evaluating the LENVIMA and KEYTRUDA combination to support 11 potential indications in six types of cancer, as well as a basket trial targeting multiple cancer types. The LENVIMA and KEYTRUDA combination is not approved in any cancer types today.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120
Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com